Delivery of nebulized budesonide is affected by nebulizer type and breathing pattern.
The aim of this study was to determine the output in-vitro of budesonide from two different nebulizers under simulated breathing conditions. The BimboNeb and Nebula nebulizers were used to nebulize 2 mL of budesonide (500 microg) suspension. Particle size was determined by inertial impaction after a 5-min nebulization. Total outputs of the drug from both nebulizers were measured using a sinus flow pump to create simulated breathing conditions. Paediatric and adult breathing patterns were used, with drug output measured after 5 and 10 min nebulization. The mass median aerodynamic diameter of budesonide using the BimboNeb (4.5 microm) was significantly greater than that from the Nebula (3.4 microm) (P<0.01). With the simulated adult breathing pattern, the total drug output after 5 min with the BimboNeb (61.5 microg) was twice that from the Nebula (30.7 microg). For the paediatric breathing pattern, total outputs were very similar for both nebulizers. In all cases, nebulizing for 10 min produced greater drug outputs compared with those after 5 min, particularly for the paediatric breathing pattern. The amount of aerosolized drug available for inhalation needs to be assessed for each nebuliser used and the effect of the patient's breathing pattern should also be taken into account.
O'Callaghan
C
C
Department of Infection, Immunity and Inflammation, Institute of Lung Health and Division of Child Health, University of Leicester, Leicester, UK. christopher.o@virgin.net
White
J
J
Jackson
J
J
Barry
P W
PW
Kantar
A
A
D000280:Administration, Inhalation; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry*; D019819:Budesonide / Q000008:administration & dosage / Q000737:chemistry*; D002648:Child; D006801:Humans; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D012119:Respiration; D013535:Suspensions
D000893:Anti-Inflammatory Agents; D013535:Suspensions; D019819:Budesonide